May 20, 2026—Anchor Molecular launched its BCR-ABL1 control panels designed to support laboratories in monitoring the performance of the quantitative detection of BCR-ABL1 translocation mRNA transcripts. The panels provide high-quality reference material for e14a2 (p210), e13a2 (p210), e1a2 (p190) transcripts, and the wildtype ABL1 control mRNA transcript. Features include purified RNA transcripts blended at 0.01 percent, 0.1 percent, and 10 percent IS (MR1.0) and values traceable to WHO International Standards (NIBSC product code: 09/138). The controls are compatible with the Cepheid Xpert BCR-ABL Ultra assay on GeneXpert systems.
Webinars and Sponsored Roundtables — Register Now
Thursday, August 20, 2026. 12 PM-1:30 PM ET
Hear from an expert in HER2 IHC whose work has contributed to current scoring guidelines.
Webinar presenter Josef Ruschoff, MD, PhD, Former Chief Medical Officer and Co-Founder of Targos, Senior Consultant of Discovery Life Sciences, Kassel, Germany.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
To be rescheduled to a future date
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.
Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY